Use of a DHODH inhibitor in combination with an inhibitor of pyrimidine salvage

US10736911B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Richard Deans · Rocky Mount, US
• Ayse Okesli · Stanford, US
• David Morgens · Stanford, US
• Chaitan Khosla · Palo Alto, US
• Michael C. Bassik · Stanford, US

Key dates

• Filing date: Dec 22, 2016
• Grant date: Aug 11, 2020
• Expiry date: Feb 23, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds and methods are provided for the treatment of pathogenic virus infections or cancer. The formulations combine an inhibitor of de novo pyrimidine synthesis, and an inhibitor of a pyrimidine salvage pathway enzyme.